| 3.7456 -0.004 (-0.12%) | 12-05 10:02 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.28 | 1-year : | 6.06 |
| Resists | First : | 4.52 | Second : | 5.19 |
| Pivot price | 3.98 |
|||
| Supports | First : | 3.44 | Second : | 2.86 |
| MAs | MA(5) : | 3.63 |
MA(20) : | 3.97 |
| MA(100) : | 3.41  |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 9.3 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 5.23 | Low : | 1.02 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PGEN ] has closed above bottom band by 37.1%. Bollinger Bands are 38.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.81 - 3.82 | 3.82 - 3.84 |
| Low: | 3.47 - 3.49 | 3.49 - 3.5 |
| Close: | 3.72 - 3.75 | 3.75 - 3.78 |
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Fri, 28 Nov 2025
Precigen (PGEN): Valuation in Focus After FDA Approval and Strengthened Cash Position - Sahm
Tue, 25 Nov 2025
Precigen Is Still A Buy After The Papzimeos Rally (NASDAQ:PGEN) - Seeking Alpha
Fri, 14 Nov 2025
Precigen, Inc. (NASDAQ:PGEN) Q3 2025 Earnings Call Transcript - Insider Monkey
Fri, 14 Nov 2025
Precigen (PGEN): HC Wainwright & Co. Adjusts Price Target to $9. - GuruFocus
Fri, 14 Nov 2025
Precigen stock holds steady as Citizens reiterates $8 price target - Investing.com
Fri, 14 Nov 2025
HC Wainwright & Co. Maintains Precigen (PGEN) Buy Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 354 (M) |
| Held by Insiders | 1.8144e+008 (%) |
| Held by Institutions | 13.6 (%) |
| Shares Short | 32,040 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0495e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 180 % |
| Return on Equity (ttm) | -52.9 % |
| Qtrly Rev. Growth | 6.31e+006 % |
| Gross Profit (p.s.) | 178.1 |
| Sales Per Share | -437.7 |
| EBITDA (p.s.) | -3.80948e+007 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -73 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 36.2 |
| Dividend | 0 |
| Forward Dividend | 2.888e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|